AxoGen, Inc. Makes First Commercial Shipment of Avance® Nerve Graft to Distributor in Italy
08:30 EDT 16 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
AxoGen, Inc. (OTCBB:AXGN), a leading regenerative medicine company
focused on the development and commercialization of products and
technologies for peripheral nerve reconstruction and regeneration, today
announced approval by t...
Other Sources for this Article
AxoGen, Inc.
Greg Freitag, 386-462-6856
Chief Financial Officer
investorrelations@axogeninc.com
www.axogeninc.com
or
Cockrell
Group
Rich Cockrell, 404-942-3369
investorrelations@thecockrellgroup.com
www.cockrellgroup.com
More From BioPortfolio on "AxoGen, Inc. Makes First Commercial Shipment of Avance® Nerve Graft to Distributor in Italy"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
